

Research Article

Time-Dependent Effects of POT1 Knockdown on Proliferation, Tumorigenicity, and HDACi Response of SK-OV3 Ovarian Cancer Cells

Hua Zhou,¹ Abdul Mondal,^{2,3} Aleksandra Dakic,^{2,3} Lama Alhawas,^{2,3}
Xuefeng Liu ^{2,3} and Zhixu He ⁴

¹Department of Obstetrics and Gynecology, Affiliated Hospital of Guizhou Medical University, Guiyang 550004, China

²Department of Pathology, Georgetown University School of Medicine, Washington, DC 20057, USA

³Center for Cell Reprogramming, Georgetown University School of Medicine, Washington, DC 20057, USA

⁴Center for Tissue Engineering and Stem Cells, Guizhou Medical University, Guiyang 550004, China

Correspondence should be addressed to Xuefeng Liu; xl24@georgetown.edu and Zhixu He; hzx671016@163.com

Received 17 September 2017; Accepted 21 December 2017; Published 6 February 2018

Academic Editor: Pauline Wimberger

Copyright © 2018 Hua Zhou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The roles of protection of telomeres 1 (POT1) in human ovarian cancer have not been fully elucidated. Here, we investigated the impact of POT1 knockdown (POT1-KD) on in vitro cell proliferation, tumorigenesis, and histone deacetylase inhibitor (HDACi) response in human ovarian cancer-derived SK-OV3 cells. The POT1 gene was knocked down by infection with POT1 lenti-shRNA. POT1, c-Myc, and hTERT mRNA levels and relative telomere length were determined by qRT-PCR; POT1 protein levels were determined by western blot. The relative telomerase activity levels were detected using qTRAP; cell proliferation was assessed using cumulative population doubling (cPD) experiments. Cell tumorigenicity was evaluated by anchorage-independent cell growth assays, and cell response to HDACi was determined by luminescence cell viability assays. Results indicate that lenti-shRNA-mediated POT1-KD significantly reduced POT1 mRNA and protein expression. POT1-KD immediately downregulated c-Myc expression, which led to the inhibition of cell proliferation, tumorigenesis, and HDACi response. However, after brief suppression, c-Myc expression increased in the medium term, which resulted in enhanced cell proliferation, tumorigenesis, and HDACi response in the POT1-KD cells. Furthermore, we discovered that c-Myc regulated cell proliferation and tumorigenesis via hTERT/telomerase/telomere pathway.

1. Introduction

Ovarian cancer is the most lethal gynecologic cancer and is the fifth most common cause of malignancy-related death in women [1]. To improve patient outcomes, researchers have focused on elucidating the mechanisms underlying cancer progression and the development of novel cancer therapies. Recently, several reports have shown that depletion of protection of telomeres 1 (POT1) fuels tumorigenesis and leads to cancer development [2, 3]. However, the role of POT1 in the malignant progression of ovarian cancer is unclear.

POT1 is a component of the nucleoprotein complexes that constitute telomeres. Crystal structural analyses have shown that the POT1 protein forms clamps for single-stranded

telomeric overhangs and binds these overhangs with exceptionally high sequence specificity [4, 5]. POT1 gene deletions affect telomere structure and function [4]. Previous studies have shown that a reduction in POT1 expression causes cellular senescence and apoptosis [6, 7]. Interestingly, several studies have recently shown that POT1 depletion fuels tumorigenesis and leads to cancer development, increases cancer cell proliferation, and enhances tumorigenicity [2, 3]. However, whether reduced POT1 expression causes cell apoptosis or promotes cell proliferation and exacerbates malignancy in ovarian cancer is unclear.

The proliferation ability and tumorigenicity of tumor cells directly affect tumor progression. c-Myc, which is associated with the malignant progression of cancer [8], binds to the

human telomerase reverse transcriptase (hTERT) promoter and positively regulates hTERT to induce telomerase reactivation or to increase telomerase activity [9, 10], each of which leads to telomere lengthening and cell proliferation. In addition, the c-Myc-mediated activation of telomerase triggers chromosome instability (CIN), which results in enhanced tumorigenicity [11, 12]. c-Myc expression is elevated in most human ovarian tumors [13]. However, the way in which c-Myc influences cell proliferation and tumorigenicity in human ovarian cancer POT1-KD cells is unknown.

The treatment of ovarian cancer is difficult for clinicians and researchers who work in the field of oncology. Some targeted therapies are already approved for ovarian cancer among the treatment of primary or recurrent disease, such as antiangiogenic therapy with bevacizumab or PARP inhibitors [14, 15]. Analyses of available data suggest that HDACs exert anticancer effects by specifically targeting transcription factors [16] and promoting deacetylation changes in these nonhistone protein substrates. JNJ-26481585 is a second-generation HDACi, and previous studies have shown that treatment with JNJ-26481585 significantly reduced the growth of rhabdomyosarcoma and lung cancer cells [17, 18]. However, little is known about the effects of JNJ-26481585 on human ovarian cancer cells.

In this study, we aimed to investigate the effects of POT1 gene expression knockdown on in vitro cell proliferation and tumorigenesis in human ovarian cancer SK-OV3 cells and to explore the role of c-Myc in these phenomena. We also investigated whether JNJ-26481585 can effectively treat human ovarian cancer POT1-KD SK-OV3 cells and elucidated the mechanism by which JNJ-26481585 exerts its effects. We hope that this in vitro study can serve as a basis for subsequent in vivo studies and even clinical trials.

2. Materials and Methods

2.1. Cell Culture and Cell Infection. The SK-OV3 cell line is a hypodiploid human ovary adenocarcinoma cell line and was obtained from the Tissue Culture Shared Resource (TCSR) at the Lombardi Comprehensive Cancer Center (LCCC; Georgetown University, District of Columbia, USA). The cells were cultured in ATCC-formulated McCoy's 5a Modified Medium (Sigma-Aldrich, USA) supplemented with 10% fetal bovine serum (Sigma-Aldrich, USA) and 10 μ g/ml gentamicin reagent solution (sc-108071, China). The cells were maintained at 37°C in a humidified incubator with 5% CO₂ and were passaged at a 1:5 ratio when they reached 80–90% confluence. We infected SK-OV3 cells with POT1 lenti-shRNA or nonspecific shRNA (Santa Cruz Biotechnology, USA). Stable clones that expressed the indicated shRNAs were selected with 1.5 μ g/ml puromycin dihydrochloride (Gibco, Canada) for 7 days until the control noninfected cells were completely dead. Selection was performed in duplicate.

2.2. Cell Proliferation Assay. Cell proliferation was assessed using cPD experiments. Cells were seeded in a 25 cm² flask (Falcon BD, USA) at a density of 50,000–100,000 cells/flask and were cultured in complete growth medium, which was replaced with 5 ml of fresh medium every 2–3 days. When

the cells reached 80–100% confluence, the number of cells per flask was determined by a Counter II FL Automated Cell Counter (Thermo Fisher, USA) and the formula $X = [\log 10(N_H) - \log 10(N_1)] / \log 10(2)$ [19] was used, where N_1 is the number of live cells in the inoculum (50,000–100,000) and N_H is the number of cells collected for analysis. To determine the total number of population doublings that the cells had experienced, we measured the population size for each passage and then compared the size of this population to those of the populations for previous passages [20]. To generate growth curves, the total number of days that elapsed between population doublings was plotted against the number of population doublings that occurred.

2.3. Quantitative Real-Time PCR (qRT-PCR). The cells were harvested, and total RNA was extracted using an RNeasy Plus Mini Kit (Qiagen, Germantown, MD, USA) according to the manufacturer's instructions. cDNA was synthesized with 3.0 μ g of RNA and a Superscript III kit (Invitrogen, USA) according to the manufacturer's protocol and was stored at –20°C until use. qRT-PCR was performed in a Bio-Rad CFX96 Real-Time System (Bio-Rad, Singapore, USA). All reactions were performed with approximately 50 ng/ml cDNA, which was obtained as described above, and were performed in triplicate. Nuclease-free water was used as a negative control, and β -2M was used as an internal control. The following primer sets (Santa Cruz Biotechnology, USA) were used: POT1, 5'-GCTTTGCATCTTTGACGTTTGA-3' (forward) and 5'-TGTGTGATGTTTCAGCCAATGC-3' (reverse); β -2M, 5'-GGACTGGTCTTTCTATCTCTTGT-3' (forward) and 5'-ACCTCCATGATGCTGCTTAC-3' (reverse); and c-Myc, 5'-ATGCCCTCAACGTTAGCTTC-3' (forward) and 5'-CTGAGACGAGGATGTTTTTGATGAAGG-3' (reverse). The primers indicated below, which were specific for hTERT mRNA and the TaqMan probe [21], were also used in the qRT-PCR assays (Roche, Indianapolis, IN, USA): forward 5'-TGACACCTCACCTCACCCAC-3' and reverse 5'-CACTGTCTTCCGCAAGTTCAC-3' and TaqMan probe 5'-ACCCTGGTCCGAGGTGTCCCTGAG-3'. The relative expression levels of the target genes were estimated using the $\Delta\Delta$ CT method. The results of this experiment were analyzed by the indicated software (Bio-Rad Laboratories, USA).

2.4. Western Blot Analysis. The western blot procedure was performed as previously described [22]. GAPDH was used as an internal control. The following antibodies were used (Santa Cruz Biotechnology, USA): anti-POT1 (dilution 1:1000), anti-rabbit IgG (dilution 1:1000), and anti-GAPDH (dilution 1:5000).

2.5. Real-Time Quantitative Telomere Repeat Amplification Protocol (qTRAP). Telomerase activity was analyzed by qTRAP. For this analysis, protein extracts were prepared from the above cells as previously described [23]. SK-OV3 cells infected with the appropriate shRNA were grown in 75 cm² tissue culture flasks (Falcon BD, USA) until they reached 80% confluence, at which time they were lysed. The cell lysates were eventually analyzed via real-time qTRAP,




FIGURE 2: POT1 mRNA expression as determined by qRT-PCR (a) and POT1 protein expression as determined by western blot analysis (b) in shRNA-infected human ovarian cancer SK-OV3 cells. POT1-KD significantly decreased cell proliferation (c) and colony formation (d) in the early POT1-KD SK-OV3 cells. “Negative control” indicates negative control SK-OV3 cells that express a nonspecific shRNA, and “POT1-KD” represents POT1-knockdown SK-OV3 cells that express POT1-specific shRNA. (c) shows the cPDs of the SK-OV3 cells. The cPDs of the negative control cells are depicted with black dots and lines, while the cPDs of the immediate effect POT1-KD cells are depicted with black squares and lines. (d) shows images from the soft agar colony formation assay that used SK-OV3 cells. The dark dots represent the colonies. Images of the negative control cells and the immediate effect POT1-KD cells were captured via digital phase-contrast microscopy at 4x magnification; scale bar: 1000 μm . ** $P < 0.01$, compared with negative control cells.

using two-tailed Student’s *t*-tests: * $P < 0.05$, ** $P < 0.01$, and *** $P > 0.05$ were considered nonsignificant.

3. Results

3.1. POT1 Knockdown (POT1-KD) Decreased Cell Proliferation and Tumorigenicity in Immediate Effect POT1-KD Cells. Human ovarian cancer SK-OV3 cells were infected with POT1 lenti-shRNA or nonspecific shRNA, the latter of which served as a negative control. We defined the cells that completed the second selection with puromycin as passage 0. To examine the effects of POT1-KD in cells, we determined the POT1 mRNA and protein levels in stably transfected SK-OV3 cells via qRT-PCR and western blot analysis, respectively. The results are expressed as percentages of the controls. POT1 transcript levels in immediate effect POT1-KD cells, which were pre-passage 11 cells and exhibited slower proliferation

than that of the negative control cells, were significantly decreased (62.89% versus 100%, ** $P < 0.01$, compared with negative control cells, Figure 2(a)). The level of POT1 protein in immediate effect POT1-KD cells was also significantly decreased (69.38% versus 100%, ** $P < 0.01$, compared with negative control cells, Figure 2(b)). The results indicated that we successfully knocked down POT1 gene expression and that POT1-KD SK-OV3 cells stably expressed POT1 shRNA.

To investigate the effect of POT1-KD on cell proliferation, we performed cPD experiments (Figure 2(c)). The data shown represent 5 population doublings. We found that the immediate effect POT1-KD cells proliferated more slowly than the negative control cells. We defined the first population doubling as 0. The cPDs of POT1-KD cells versus negative control cells were 1.15 versus 2.71 in the 2nd cPD, 2.41 versus 5.88 in the 3rd cPD, 3.77 versus 8.11 in the 4th cPD, and 5.15 versus 11.35 in the 5th cPD. In vitro growth curves




FIGURE 3: Decreased c-Myc expression resulted in hTERT inhibition and reductions in telomerase activity and telomere length in the immediate effect POT1-KD cells. The mRNA expression levels of c-Myc and hTERT in the immediate effect POT1-KD cells and negative control cells (a); the relative telomerase activity levels in the immediate effect POT1-KD cells and negative control cells (b); and the relative telomere lengths in the immediate effect POT1-KD cells and negative control cells (c). ** $P < 0.01$, compared with negative control cells.

suggested that the reduction of POT1 expression decreased cell proliferation in immediate effect POT1-KD cells.

The anchorage-independent growth of cancer cells, which is closely correlated with self-renewal and metastasis, reflects the tumorigenicity of these cells [24]. Low-efficiency cell colony formation in soft agar is attributed to mitigated tumorigenicity. To explore the effect of POT1-KD on cell tumorigenicity, we examined the anchorage-independent growth of SK-OV3 cells using a soft agar assay. The cells were plated and cultured in soft agar for 3 weeks. As shown in Figure 2(d), fewer and smaller colonies were formed by immediate effect POT1-KD cells than by negative control cells. The relative colony formation rate of POT1-KD cells was expressed as a percentage of the relative colony formation rate of negative control cells. Compared with the relative colony formation rate in the negative control cells, the relative colony formation rate in immediate effect POT1-KD cells was significantly decreased (53.75% versus 100%, ** $P < 0.01$). These data indicated that suppressing POT1 expression decreased the tumorigenicity in the immediate effect POT1-KD cells.

3.2. POT1 Downregulation Immediately Resulted in a Reduction of SK-OV3 Cell Proliferation and Tumorigenicity via Impairment of c-Myc. To elucidate the molecular mechanism that underlies the POT1 downregulation-induced inhibition of cell proliferation and tumorigenicity, we evaluated the transcription levels of c-Myc, which plays a critical role in the proliferation and tumorigenicity of cancer cells [25]. We examined the level of c-Myc mRNA in immediate effect POT1-KD cells via qRT-PCR and expressed the value as a percentage of the negative control. Compared with the mean percentage of c-Myc mRNA expression in the negative control cells, the mean percentage of c-Myc mRNA expression in immediate effect POT1-KD cells was significantly decreased (44.33% versus 100%, ** $P < 0.01$, Figure 3(a)). These results indicated that POT1-KD decreased c-Myc expression.

hTERT is a downstream gene of c-Myc. The hTERT gene expression levels were determined via qRT-PCR, which showed that hTERT levels were lower in immediate effect POT1-KD cells (61.85% versus 100%, $P < 0.01$) than in the negative control cells (Figure 3(a)). This result indicated that




FIGURE 4: Medium-term effect POT1-KD SK-OV3 cells displayed increased cell proliferation and more severe tumorigenicity than negative control cells. As shown in the cPD experiments, the cPDs of the negative control cells are depicted with black dots and lines, while the cPDs of the medium-term effect POT1-KD cells are depicted with black squares and lines (a). Images of the negative control and the medium-term effect POT1-KD cells were captured via digital phase-contrast microscopy at 4x magnification; scale bar: 1000 μm . The dark dots represent the colonies in soft agar (b). * $P < 0.05$, compared with negative control cells.

decreases in c-Myc expression resulted in decreases in hTERT mRNA expression in immediate effect POT1-KD cells.

A growing body of evidence indicates that hTERT plays important roles in the promotion of telomerase activity and in telomere maintenance [26, 27]. Relative telomerase activity levels in SK-OV3 cells were detected using the qTRAP assay. The results showed that, compared with the telomerase activity in the negative control cells, the telomerase activity in the immediate effect POT1-KD cells was decreased (160.5 ± 2.1 ng versus 1110 ± 7.1 ng, $P < 0.01$, Figure 3(b)). Telomere length was assessed in SK-OV3 cells using a qRT-PCR-based telomere length assay. The results showed that the telomere length was shorter in the immediate effect POT1-KD cells than that in the negative control cells (0.760 ± 0.006 versus 0.781 ± 0.003 , $P < 0.01$, Figure 3(c)).

3.3. After Brief Repression, In Vitro Cell Growth Curves Showed That the Proliferation of POT1-KD Cells Increased, and Medium-Term Effect POT1-KD Cells Exhibited More Severe Tumorigenicity Than Their Counterparts. cPD experiments were performed again (Figure 4(a)). In these cPD experiments using knockdown and negative control cells, 5 completed population doublings were observed. We defined the first population doubling as 0. The cPDs of POT1-KD cells versus negative control cells were 4.98 versus 2.60 in the 2nd cPD, 10.11 versus 5.62 in the 3rd cPD, 16.12 versus 9.08 in the 4th cPD, and 22.17 versus 12.36 in the 5th cPD. The results of these cPD experiments showed that the POT1-KD cells proliferated more rapidly than negative control cells. Thus, we referred to these POT1-KD cells as “medium-term effect POT1-KD cells.”

Regarding the anchorage-independent growth shown in Figure 3(b), the obtained images showed that medium-term effect POT1-KD cells formed significantly more colonies and larger colonies in soft agar than negative control cells.

Compared with the relative colony formation rate in the negative control cells, the relative colony formation rate in the medium-term effect POT1-KD cells was significantly increased (143.52% versus 100%, * $P < 0.05$). These data suggested that, compared with the negative control cells, the medium-term effect POT1-KD cells exhibited enhanced tumorigenicity.

3.4. c-Myc Expression Was Significantly Increased, but POT1 Transcription Remained Lower in the Medium-Term Effect POT1-KD Cells Than That in the Negative Control Cells, and Ultimately POT1 Suppression Promoted Cell Proliferation and Tumorigenicity via the Upregulation of c-Myc. To assess the efficiency of POT1-KD in the medium-term effect POT1-KD cells, we repeated the qRT-PCR analysis. Compared with the mean percentages of POT1 mRNA expression in the negative control cells, the mean percentages of POT1 mRNA expression in the medium-term effect POT1-KD cells remained significantly decreased (67.78% versus 100%, ** $P < 0.01$, Figure 5(a)). Conversely, compared with the c-Myc mRNA expression levels in the negative control cells, the c-Myc mRNA expression levels in the medium-term effect POT1-KD cells were significantly increased (136.41% versus 100%, $P < 0.01$, Figure 5(a)).

In conjunction with the increases in c-Myc expression, compared with the hTERT expression in the negative control cells, hTERT expression in the medium-term effect POT1-KD cells was also increased (145.24% versus 100%, $P < 0.01$, Figure 5(a)). This result indicated that POT1 shRNA was still effective in the medium-term effect POT1-KD cells. At the same time, the medium-term effect POT1-KD cells possessed higher telomerase activity, which was nearly 2.0-fold higher (1830 ± 125 ng versus 950 ± 221 ng, $P < 0.01$) than the telomerase activity in negative control cells (Figure 5(b)). Furthermore, compared with the telomere length in the negative





FIGURE 5: POT1 mRNA expression was reduced, whereas c-Myc mRNA expression was increased in the medium-term effect POT1-KD cells, and as a result of the increase in c-Myc, hTERT mRNA expression was upregulated, telomerase activity was increased, and telomeres were elongated in the medium-term effect POT1-KD cells. The mRNA expression levels of POT1, c-Myc, and hTERT in the medium-term effect POT1-KD cells and negative control cells (a); the relative telomerase activity levels in the medium-term effect POT1-KD cells and negative control cells (b); and the relative telomere lengths in the medium-term effect POT1-KD cells and negative control cells (c). ** $P < 0.01$, compared with negative control cells.


control cells, the telomere length in the medium-term effect POT1-KD cells was increased (0.765 ± 0.003 versus 0.742 ± 0.001 , $P < 0.01$, Figure 5(c)).

3.5. Silencing POT1 Repressed Sensitivity to Anticancer Agent in the Immediate Effect POT1-KD Cells but Ultimately Enhanced the Sensitivity of the Medium-Term Effect POT1-KD Cells to the Antitumor Drug JNJ-26481585, Which Was Likely due to a Different c-Myc Transcriptional Level in the POT1-KD Cells. Some reports identified a specific effect of the second-generation histone deacetylase inhibitor JNJ-26481585 to trigger apoptosis in rhabdomyosarcoma and lung cancer cells [17, 18]. In order to address the question of whether JNJ-26481585 can kill SK-OV3 ovarian cancer cells, we tested the effects of JNJ-26481585 alone for the treatment of SK-OV3 ovarian cancer cells. The sensitivity of SK-OV3 cells to JNJ-26481585 was determined by luminescence cell viability assays. SK-OV3 cells were plated in 96-well plates


and treated with different concentrations of JNJ-26481585 or the same quantities of DMSO for 48 h. The relative cell viability and the IC₅₀ values for cells served as indices of the sensitivity of POT1-KD cells to JNJ-26481585. Figures 6(a) and 6(b) show that JNJ-26481585 induced SK-OV3 apoptosis in a dose-dependent manner. Cells were treated with JNJ-26481585, the concentration of which varied from $0.63 \mu\text{M}$ to $5 \mu\text{M}$. Compared with the viability of the negative control cells, the viability of the immediate effect POT1-KD cells was significantly enhanced and the viability of the medium-term effect POT1-KD cells was significantly decreased (** $P < 0.01$ or * $P < 0.05$). However, when cells were treated with JNJ-26481585, the concentration of which varied from $10 \mu\text{M}$ to $40 \mu\text{M}$, there were no statistical differences in the viability of cells between the negative control cells and the POT1-KD cells (** $P > 0.05$). Figures 6(c) and 6(d) show that the IC₅₀ value of the immediate effect POT1-KD cells was increased ($0.83 \pm 0.08 \mu\text{M}$ versus $0.39 \pm 0.13 \mu\text{M}$, * $P < 0.05$) and was




(a)




(b)




(c)



(d)



(e)



(f)

FIGURE 6: Continued.




FIGURE 6: Knockdown of the POT1 gene induced a transient inhibitory effect on the JNJ-26481585 response of SK-OV3 cells, and c-Myc played an important role in the sensitization of SK-OV3 cells to the antitumor agent JNJ-26481585. The relative cell viability of the immediate effect POT1-KD cells and negative control cells (a) and the relative cell viability of the medium-term effect POT1-KD cells and negative control cells (b); the IC₅₀ values of the immediate effect POT1-KD cells and negative control cells (c) and the IC₅₀ values of the medium-term effect POT1-KD cells and negative control cells (d); the c-Myc mRNA expression levels in the immediate effect POT1-KD cells and negative control cells treated with JNJ-26481585 (e); the c-Myc mRNA expression levels in the medium-term effect POT1-KD cells and negative control cells treated with JNJ-26481585 (f); the c-Myc mRNA expression levels in the immediate effect POT1-KD cells and negative control cells before JNJ-26481585 treatment (g); the c-Myc mRNA expression levels in the medium-term effect POT1-KD cells and negative control cells before JNJ-26481585 treatment (h). * $P < 0.05$, ** $P < 0.01$, and *** $P > 0.05$, compared with negative control cells.

approximately 2-fold higher than that in the corresponding negative control cells, while the IC₅₀ value of the medium-term effect POT1-KD cells was decreased ($0.34 \pm 0.10 \mu\text{M}$ versus $1.07 \pm 0.12 \mu\text{M}$, * $P < 0.05$) and was approximately 3-fold lower than that in the corresponding negative control cells. Interestingly, Figures 6(a), 6(b), 6(c), and 6(d) show that the effects of JNJ-26481585-induced cell apoptosis were reduced in the immediate effect POT1-KD cells but that the effects were enhanced in the medium-term effect POT1-KD cells. The data suggested that the immediate effect POT1-KD cells exhibited chemotherapy resistance, while the medium-term effect POT1-KD cells exhibited chemotherapy sensitivity.

To further study the relationship between the cellular response to JNJ-26481585 and the genes involved in intrinsic cell apoptosis, we used qRT-PCR to determine the c-Myc levels, which are expressed as percentages of the corresponding levels in negative control cells. As shown in Figures 6(e) and 6(f), the c-Myc gene expression levels in both groups of negative control cells and in both groups of POT1-KD cells were significantly reduced after JNJ-26481585 treatment compared with before JNJ-26481585 treatment (** $P < 0.01$). These results suggested that JNJ-26481585 can target the transcription of c-Myc. Before JNJ-26481585 treatment, c-Myc transcription levels in the immediate effect POT1-KD cells were lower (64.18% versus 100%, ** $P < 0.01$, Figure 6(g)) than those in the corresponding negative control cells. However, compared with the c-Myc gene transcription levels in the corresponding negative control cells, the c-Myc gene transcription levels in the medium-term effect POT1-KD cells were increased (136.22% versus 100%, ** $P < 0.01$,

Figure 6(h)). Taken together, these findings indicated that lower c-Myc expression was closely associated with higher cell viability and resistance to JNJ-26481585 in the immediate effect POT1-KD cells, while higher c-Myc expression was closely associated with lower cell viability and sensitivity to JNJ-26481585 in the medium-term effect POT1-KD cells.

4. Discussion

POT1 protein, a single-stranded telomeric DNA-binding protein, plays an important role in telomere protection and in the regulation of telomere length [28]. Previous studies have suggested that the inhibition of POT1 expression is associated with apoptosis or proliferation of tumor cells; however, the role of POT1 in human ovarian cancer remains unclear.

In this study, the data suggested that reduced POT1 expression in the immediate effect POT1-KD cells, which referred to pre-passage 11 cells that exhibited slower growth than that in the control cells, as described previously, caused decreases in cell proliferation and tumorigenicity. These changes were consistent with those noted in a study by Veldman et al. [29]. The POT1 protein can bind to 3'-overhangs in the form of a quadruplex [28, 30], which has been observed in the promoter region of c-Myc [31]. The knockdown of POT1 gene expression changed the spatial conformation of the quadruplex and thus affected the function of the c-Myc promoter, which directly resulted in the downregulation of c-Myc mRNA expression [28, 30, 31]. Subsequently, the transcription of hTERT, a downstream gene of c-Myc [9, 10], was also decreased. As a result, hTERT-dependent

telomerase activity was decreased. High telomerase activity triggers CIN and consequently increases tumorigenicity [11, 12]. In this study, impaired c-Myc reduced tumorigenicity via the reduction of telomerase activity in the immediate effect POT1-KD cells. Telomerase maintains telomere length in cancer cells, thereby supporting cell proliferation [32]. Furthermore, reduced telomerase activity causes decreased telomere length, and shortened telomeres contribute to restricted cell proliferation. Thus, the evidence suggested that knockdown of POT1 impaired c-Myc expression, which reduced cell proliferation and tumorigenicity via suppression of the hTERT/telomerase/telomere pathway in the immediate effect POT1-KD cells.

We defined these POT1-KD cells, which proliferated more rapidly than negative control cells, as “medium-term effect POT1-KD cells.” At the same time, as shown in Figure 3, anchorage-independent growth analyses showed that, compared with the negative control cells, the medium-term effect POT1-KD cells exhibited enhanced tumorigenicity. qRT-PCR analysis showed that the expression of POT1 mRNA was significantly reduced in the medium-term effect POT1-KD cells, which indicates that the POT1 shRNA was still effective in these cells and that the increased proliferation and tumorigenicity in the medium-term effect POT1-KD cells were not caused by nonfunctional shRNA-POT1. Contrary to the result of POT1 mRNA expression, c-Myc mRNA transcription levels were significantly increased. Enhanced c-Myc expression in tumor cells occurs via multiple mechanisms, such as gene amplification, chromosomal rearrangement, single-nucleotide mutations, and enhancement of c-Myc protein stability [33–36]. However, the mechanisms that underlie the increase in c-Myc expression noted in this study are unclear and warrant further study. Due to the increased c-Myc transcription, hTERT expression was enhanced, and consequently telomerase activity was promoted and telomeres were extended. In cancer cells, telomere length is determined mainly by telomerase-dependent DNA elongation and erosion, which result from incomplete DNA replication [37]. Thus, when telomerase activity is enhanced in cancer cells, telomere length does not undergo the typical continuous yet slow decrease. Instead, telomere length remains unchanged or increases. In this study, the data indicated that the significantly longer telomeres of the medium-term effect POT1-KD cells compared with those of the negative control cells resulted from increases in telomerase activity. The results of a previous study showed that c-Myc gene transcription was almost undetectable in quiescent cells but was rapidly induced upon mitogenic stimulation [38]; c-Myc then promoted cell proliferation via the hTERT signaling pathway in cancer cells [9, 10]. Our results were similar to those of the indicated studies and suggested that c-Myc upregulation enhanced hTERT pathway-mediated cell proliferation in the medium-term effect POT1-KD cells. High-efficiency cell colony formation in soft agar is attributed to greater tumorigenicity, which is characterized by self-renewal and metastasis [39]. Our data indicated that, in the presence of higher c-Myc expression, hTERT expression was amplified, and telomerase activity was enhanced in the medium-term effect POT1-KD cells. Consequently, the

medium-term effect POT1-KD cells produced significantly more colonies and larger colonies in soft agar compared with the negative control cells. These findings suggested that the knockdown of POT1 gene expression ultimately led to increased tumorigenicity via the amplification of c-Myc.

Many studies have indicated that POT1 gene dysfunction in malignant human tumor cells induces senescence and apoptosis [40, 41]. However, recent studies have shown that the repression of POT1 expression can result in tumor progression [2, 3]. In this study, we showed for the first time that reduced POT1 expression in ovarian cancer SK-OV3 cells immediately resulted in temporary inhibition of proliferation and tumorigenicity but ultimately led to enhanced proliferation and tumorigenicity. Furthermore, we found that changes in c-Myc transcription were responsible for these biological phenomena, which occurred via the regulation of the hTERT/telomerase/telomere pathway. Thus, decreased POT1 expression is likely a catastrophic event in ovarian cancer progression because it results in c-Myc dysregulation.

Ovarian cancer is characterized by CIN, a phenomenon that can augment ovarian cancer progression [42]. Our data mentioned above also indicate that POT1-KD enhanced ovarian cancer cell proliferation and oncogenicity through the upregulation of c-Myc. c-Myc is among the most frequently overexpressed genes in human ovarian cancer [43], and it activates the transcription of downstream genes by binding to CACGTG motifs [44]. Therefore, the identification of effective agents that inhibit c-Myc expression is very important to block ovarian cancer progression. However, it is difficult to design inhibitory small molecules that target c-Myc because its protein lacks enzymatic activity and it functions primarily through protein-DNA and protein-protein interactions. Enzymes that catalyze the deacetylation of nucleosomal histones can also modify nonhistone substrates, such as c-Myc, and therefore they are able to regulate c-Myc expression. Several HDACs have already been shown to effectively reduce c-Myc protein levels by directly inducing hyperacetylation and suppressing its transcription [45]. There is growing evidence that JNJ-26481585 alters broad enzyme inhibitory activity in the low nanomolar range and plays a fundamental role in the regulation of c-Myc gene expression governed by epigenetic changes [46]. JNJ-26481585 results in hyperacetylation of c-Myc and subsequent polyubiquitylation and proteasomal degradation of client proteins. This effect is directly related to the proapoptotic activities of the cells [47]. In addition to c-Myc suppression, JNJ-26481585 may have other confounding effects, for example, inducing apoptosis. JNJ-26481585 has been shown to induce morphologic and biochemical changes associated with apoptosis [17, 46, 47]. JNJ-26481585 can elicit diverse biological responses, such as suppression of cell proliferation, induction of cellular differentiation or induction of cellular apoptosis *in vitro*, inhibition of angiogenesis, and modulation of immune responses *in vivo*. In therapy studies using a mouse model of B-cell lymphoma, results showed a direct correlation between the induction of tumor cell death by JNJ-26481585 *in vitro* and therapeutic benefit *in vivo* [48]. JNJ-26481585, as a novel second-generation HDAC inhibitor, exhibits broad-spectrum antiproliferative activity in solid and hematologic cancer cell lines including ovarian tumor cell

lines. This effect was also observed with in vivo ovarian cancer model [49]. In our study, after JNJ-26481585 treatment, c-Myc mRNA expression was significantly downregulated in all treated cells. The data indicated that JNJ-26481585 induced SK-OV3 cell death by targeting c-Myc. Furthermore, in the POT1-KD cells and negative control cells, higher c-Myc expression was always associated with lower cell survival. These findings further confirmed that JNJ-26481585 induced apoptosis in SK-OV3 cells by c-Myc-mediated inhibition. JNJ-26481585 is a promising agent that may be used to arrest ovarian cancer development, and c-Myc is the putative therapeutic target and should be a response predictor for JNJ-26481585 treatment independently of POT1 status. The medium-term effect POT1-KD cells were associated with more severe malignancy, but fortunately amplification of c-Myc enhanced their anticancer activity to JNJ-26481585.

5. Conclusions

In summary, our findings indicated that POT1 knockdown resulted in a time-dependent effect on proliferation, tumorigenicity, and HDACi response in SK-OV3 ovarian cancer cells via the regulation of c-Myc. Furthermore, we discovered that c-Myc regulated cell proliferation and tumorigenesis via hTERT/telomerase/telomere pathway.

Abbreviations

POT1:	Protection of telomeres 1
POT1-KD:	POT1 knockdown
qRT-PCR:	Quantitative real-time PCR
qTRAP:	Real-time quantitative telomere repeat amplification protocol
cPD:	Cumulative population doubling
hTERT:	Human telomerase reverse transcriptase
CIN:	Chromosome instability
HDACi:	Histone deacetylase inhibitor
DMSO:	Dimethylsulfoxide
IC50:	Half-maximal inhibitory concentration.

Ethical Approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Conflicts of Interest

All authors declare that they have no conflicts of interest.

Acknowledgments

The authors are grateful to Dr. Ewa Krawczyk at Georgetown University for the services and facilities provided. This work was supported by the National Natural Science Foundation of China (Grant no. NSFC 31360285), the Major Basic Research Program of Guizhou Province (Grant no. Qian Ke He J Major (2015) 2003), and the Joint Fund of Guiyang Science and Technology Bureau and Guizhou Medical University of China (Grant no. GY2015-20).

References

- [1] T. H. Kim, D. H. Suh, M.-K. Kim, and Y. S. Song, "Metformin against cancer stem cells through the modulation of energy metabolism: special considerations on ovarian cancer," *BioMed Research International*, vol. 2014, Article ID 132702, 2014.
- [2] A. M. Pinzaru, R. A. Hom, A. Beal et al., "Telomere replication stress induced by POT1 inactivation accelerates tumorigenesis," *Cell Reports*, vol. 15, no. 10, pp. 2170–2184, 2016.
- [3] P. Gu, Y. Wang, K. K. Bisht et al., "Pot1 OB-fold mutations unleash telomere instability to initiate tumorigenesis," *Oncogene*, vol. 36, no. 14, pp. 1939–1951, 2016.
- [4] P. Baumann and T. R. Cech, "Pot1, the putative telomere end-binding protein in fission yeast and humans," *Science*, vol. 292, no. 5519, pp. 1171–1175, 2001.
- [5] M. Lei, E. R. Podell, P. Baumann, and T. R. Cech, "DNA self-recognition in the structure of Pot1 bound to telomeric single-stranded DNA," *Nature*, vol. 426, no. 6963, pp. 198–202, 2003.
- [6] Q. Yang, Y.-L. Zheng, and C. C. Harris, "POT1 and TRF2 cooperate to maintain telomeric integrity," *Molecular and Cellular Biology*, vol. 25, no. 3, pp. 1070–1080, 2005.
- [7] S.-M. Wan, J. Tie, Y.-F. Zhang et al., "Silencing of the hPOT1 gene by RNA interference promotes apoptosis and inhibits proliferation and aggressive phenotype of gastric cancer cells, likely through up-regulating PinX1 expression," *Journal of Clinical Pathology*, vol. 64, no. 12, pp. 1051–1057, 2011.
- [8] Y. Yoo, M. Hayashi, J. Christensen, and L. E. Huang, "An essential role of the HIF-1 α -c-Myc axis in malignant progression," *Annals of the New York Academy of Sciences*, vol. 1177, pp. 198–204, 2009.
- [9] A. E. Bilsland, S. Hoare, K. Stevenson et al., "Dynamic telomerase gene suppression via network effects of GSK3 inhibition," *PLoS ONE*, vol. 4, no. 7, Article ID e6459, 2009.
- [10] P. Dasgupta and S. Sengupta Bandyopadhyay, "Role of diallyl disulfide-mediated cleavage of c-Myc and Sp-1 in the regulation of telomerase activity in human lymphoma cell line U937," *Nutrition Journal*, vol. 31, no. 7-8, pp. 1031–1037, 2015.
- [11] A. V. Bazarov, W. C. Hines, R. Mukhopadhyay et al., "Telomerase activation by c-Myc in human mammary epithelial cells requires additional genomic changes," *Cell Cycle*, vol. 8, no. 20, pp. 3373–3378, 2009.
- [12] A. Kuzyk and S. Mai, "c-MYC-induced genomic instability," *Cold Spring Harbor Perspectives in Medicine*, vol. 4, no. 4, p. a014373, 2014.
- [13] T. Prathapam, A. Aleshin, Y. Guan, J. W. Gray, and G. S. Martin, "p27Kip1 mediates addiction of ovarian cancer cells to MYCC (c-MYC) and their dependence on MYC paralogs," *The Journal of Biological Chemistry*, vol. 285, no. 42, pp. 32529–32538, 2010.
- [14] S. Schott, P. Wimberger, B. Klink et al., "The conjugated anti-metabolite 5-FdU-ECyd and its cellular and molecular effects on platinum-sensitive vs. -resistant ovarian cancer cells *in vitro*," *Oncotarget*, vol. 8, no. 44, pp. 76935–76948, 2017.
- [15] P. Wimberger, I. Chebouti, S. Kasimir-Bauer et al., "Explorative investigation of vascular endothelial growth factor receptor expression in primary ovarian cancer and its clinical relevance," *Gynecologic Oncology*, vol. 133, no. 3, pp. 467–472, 2014.
- [16] S. Robson, S. Pelengaris, and M. Khan, "c-Myc and downstream targets in the pathogenesis and treatment of cancer," *Recent Patents on Anti-Cancer Drug Discovery*, vol. 1, no. 3, pp. 305–326, 2006.
- [17] U. Heinicke, J. Kupka, I. Fichter, and S. Fulda, "Critical role of mitochondria-mediated apoptosis for JNJ-26481585-induced

- antitumor activity in rhabdomyosarcoma," *Oncogene*, vol. 35, no. 28, pp. 3729–3741, 2015.
- [18] L. Bao, H. Diao, N. Dong et al., "Histone deacetylase inhibitor induces cell apoptosis and cycle arrest in lung cancer cells via mitochondrial injury and p53 up-acetylation," *Cell Biology and Toxicology*, vol. 32, no. 6, pp. 469–482, 2016.
- [19] S. Xue, H.-T. Zhang, P. Zhang et al., "Functional endothelial progenitor cells derived from adipose tissue show beneficial effect on cell therapy of traumatic brain injury," *Neuroscience Letters*, vol. 473, no. 3, pp. 186–191, 2010.
- [20] U. Nekanti, S. Dastidar, P. Venugopal, S. Totey, and M. Ta, "Increased proliferation and analysis of differential gene expression in human Wharton's jelly-derived mesenchymal stromal cells under hypoxia," *International Journal of Biological Sciences*, vol. 6, no. 5, pp. 499–512, 2010.
- [21] X. Liu, J. Roberts, A. Dakic, Y. Zhang, and R. Schlegel, "HPV E7 contributes to the telomerase activity of immortalized and tumorigenic cells and augments E6-induced hTERT promoter function," *Virology*, vol. 375, no. 2, pp. 611–623, 2008.
- [22] K. Fujita, A. M. Mondal, I. Horikawa et al., "p53 isoforms $\Delta 133p53$ and p53 β are endogenous regulators of replicative cellular senescence," *Nature Cell Biology*, vol. 11, no. 9, pp. 1135–1142, 2009.
- [23] J. Miller, A. Dakic, R. Chen et al., "HPV16 E7 protein and hTERT proteins defective for telomere maintenance cooperate to immortalize human keratinocytes," *PLoS Pathogens*, vol. 9, no. 4, p. e1003284, 2013.
- [24] C. A. Thibodeaux, X. Liu, G. L. Disbrow et al., "Immortalization and transformation of human mammary epithelial cells by a tumor-derived Myc mutant," *Breast Cancer Research and Treatment*, vol. 116, no. 2, pp. 281–294, 2009.
- [25] J. Kim, M. Roh, and S. A. Abdulkadir, "Pim1 promotes human prostate cancer cell tumorigenicity and c-MYC transcriptional activity," *BMC Cancer*, vol. 10, article no. 248, 2010.
- [26] M. A. Jafri, S. A. Ansari, M. H. Alqahtani, and J. W. Shay, "Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies," *Genome Medicine*, vol. 8, no. 1, article no. 69, 2016.
- [27] D. E. MacNeil, H. J. Bensoussan, and C. Autexier, "Telomerase regulation from beginning to the end," *Gene*, vol. 7, no. 9, article no. 64, 2016.
- [28] H. Hwang, N. Buncher, P. L. Opreko, and S. Myong, "POT1-TPPI regulates telomeric overhang structural dynamics," *Structure*, vol. 20, no. 11, pp. 1872–1880, 2012.
- [29] T. Veldman, K. T. Etheridge, and C. M. Counter, "Loss of hPot1 function leads to telomere instability and a cut-like phenotype," *Current Biology*, vol. 14, no. 24, pp. 2264–2270, 2004.
- [30] M. P. Horvath and S. C. Schultz, "DNA G-quartets in a 1.86 Å resolution structure of an *Oxytricha nova* telomeric protein-DNA complex," *Journal of Molecular Biology*, vol. 310, no. 2, pp. 367–77, 2001.
- [31] T. Hao, V. C. Gaerig, and T. A. Brooks, "Nucleic acid clamp-mediated recognition and stabilization of the physiologically relevant MYC promoter G-quadruplex," *Nucleic Acids Research*, vol. 44, no. 22, pp. 11013–11023, 2016.
- [32] M. Ivancich, Z. Schrank, L. Wojdyla et al., "Treating cancer by targeting telomeres and telomerase," *Antioxidants*, vol. 6, no. 1, article no. 15, 2017.
- [33] M. Eilers and R. N. Eisenman, "Myc's broad reach," *Genes & Development*, vol. 22, no. 20, pp. 2755–2766, 2008.
- [34] N. Meyer and L. Z. Penn, "Reflecting on 25 years with MYC," *Nature Reviews Cancer*, vol. 8, no. 12, pp. 976–990, 2008.
- [35] M. M. Pomerantz, N. Ahmadiyeh, L. Jia et al., "The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer," *Nature Genetics*, vol. 41, no. 8, pp. 882–884, 2009.
- [36] J. B. Wright, S. J. Brown, and M. D. Cole, "Upregulation of c-MYC in cis through a large chromatin loop linked to a cancer risk-associated single-nucleotide polymorphism in colorectal cancer cells," *Molecular and Cellular Biology*, vol. 30, no. 6, pp. 1411–1420, 2010.
- [37] J. A. Stewart, M. F. Chaiken, F. Wang, and C. M. Price, "Maintaining the end: roles of telomere proteins in end-protection, telomere replication and length regulation," *Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis*, vol. 730, no. 1-2, pp. 12–19, 2012.
- [38] X. Wang, L. Sun, X. Wang et al., "Acidified bile acids enhance tumor progression and telomerase activity of gastric cancer in mice dependent on c-Myc expression," *Cancer Medicine*, vol. 6, no. 4, pp. 788–797, 2017.
- [39] S. Zhang, Y. Shang, T. Chen et al., "Human circulating and tissue gastric cancer stem cells display distinct epithelial-mesenchymal features and behaviors," *Journal of Cancer Research and Clinical Oncology*, vol. 143, no. 9, pp. 1687–1699, 2017.
- [40] Y. Deng, S. S. Chan, and S. Chang, "Telomere dysfunction and tumour suppression: the senescence connection," *Nature Reviews Cancer*, vol. 8, no. 6, pp. 450–458, 2008.
- [41] H. Takai, E. Jenkinson, S. Kabir et al., "A POT1 mutation implicates defective telomere end fill-in and telomere truncations in coats plus," *Genes & Development*, vol. 30, no. 7, pp. 812–826, 2016.
- [42] S. Penner-Goeke, Z. Lichtensztejn, M. Neufeld et al., "The temporal dynamics of chromosome instability in ovarian cancer cell lines and primary patient samples," *PLoS Genetics*, vol. 13, no. 4, p. e1006707, 2017.
- [43] H. Qiu, A. L. Jackson, J. E. Kilgore et al., "JQ1 suppresses tumor growth through downregulating LDHA in ovarian cancer," *Oncotarget*, vol. 6, no. 9, pp. 6915–6930, 2015.
- [44] C. Y. Lin, J. Lovén, P. B. Rahl et al., "Transcriptional amplification in tumor cells with elevated c-Myc," *Cell*, vol. 151, no. 1, pp. 56–67, 2012.
- [45] A. Nebbioso, V. Carafa, M. Conte et al., "c-Myc modulation and acetylation is a key hdac inhibitor target in cancer," *Clinical Cancer Research*, vol. 23, no. 10, pp. 2542–2555, 2017.
- [46] J. Bhadury, L. M. Nilsson, S. V. Muralidharan et al., "BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 111, no. 26, pp. E2721–E2730, 2014.
- [47] L. Ellis, M. Bots, R. K. Lindemann et al., "The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy," *Blood*, vol. 114, no. 2, pp. 380–393, 2009.
- [48] R. K. Lindemann, A. Newbold, K. F. Whitecross et al., "Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 104, no. 19, pp. 8071–8076, 2007.
- [49] J. Arts, P. King, A. Mariën et al., "JNJ-26481585, a novel "second-generation" oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity," *Clinical Cancer Research*, vol. 15, no. 22, pp. 6841–6851, 2009.



Hindawi

Submit your manuscripts at
www.hindawi.com

